Dr. Jay Yang has served as the Vice President of Biostatistics and Data Management since May 2022. He has two decades of experience working and managing biostatistical and programming in big pharmaceutical and biotech companies in oncology, respiratory, dermatology, women’s health, vaccine, and virology therapeutical areas. Prior to joining Altimmune, Dr. Yang served as VP of Biostatistics for Epizyme Inc, where he led two successful NDA/sNDA filings and supported Epizyme’s successful FDA ODAC voting meeting (11 Yes vs. 0 No). Prior to Epizyme, he led similar groups at major pharmaceutical companies, including Medimmune/AstraZeneca, Eisai, NPS, Roche, and Novartis. Jay holds a PhD in Statistics from Florida State University, and a BS from Peking University (Beijing, China). Dr Yang has 20 plus peer-reviewed journal publications and has been an author for two recent Lancet oncology publications.
